Company: INMB
Filing Date: 2025-06-16
Form Type: S-8
Source: 0001213900-25-054428
Chunk: 2

Company: Inmune Bio, Inc.
Filing Date: 2025-06-16
Form: S-8
Chunk 2
---
1. Plan Information.

INmune Bio Inc. will provide each participant
(the “Recipient”) with documents that contain information related to the 2017 Plan and 2019 Plan, and other information including,
but not limited to, the disclosure required by Item 1 of Form S-8, which information is not filed as a part of this Registration Statement
on Form S-8. The foregoing information and the documents incorporated by reference in response to Item 3 of Part II of this Registration
Statement taken together constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. A Section 10(a) prospectus
will be given to each Recipient who receives shares of common stock covered by this Registration Statement, in accordance with Rule 428(b)(1)
under the Securities Act.

Item 2. Registrant Information and Employee Plan Annual Information.

We will provide to each Recipient a written statement
advising it of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement and of documents
required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral notice by contacting:

<div align='center'>INmune Bio Inc.

225 NE Mizner Blvd., Suite
640

Boca Raton, FL 33432

Attention: Corporate Secretary

Telephone: (561) 710-0512</div>

Information required by Part I to be contained in Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule 428 under the Securities Act.

REOFFER PROSPECTUS

<div align='center'>INmune Bio Inc.

3,324,550 Shares of Common Stock</div>

This reoffer prospectus relates to the aggregate
sale of 3,324,550 shares of our common stock that may be offered and resold from time to time by the selling stockholders identified in
this reoffer prospectus for their own account. Such shares have been or may be acquired in connection with 1,592,000 awards granted under
the 2017 Plan) and 1,732,550 awards granted under the 2019 Plan. It is anticipated that the selling stockholders will offer shares for
sale at prevailing prices on the Nasdaq Capital Market on the date of sale. We will receive no part of the proceeds from sales made under
this reoffer prospectus. The selling stockholders will bear all sales commissions and similar expenses